{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:39:42Z","timestamp":1761647982261,"version":"3.40.3"},"reference-count":150,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.lpm.2012.05.024","type":"journal-article","created":{"date-parts":[[2012,7,24]],"date-time":"2012-07-24T21:16:19Z","timestamp":1343164579000},"page":"e495-e509","source":"Crossref","is-referenced-by-count":13,"special_numbering":"P2","title":["Biologic treatments in Sj\u00f6gren's syndrome"],"prefix":"10.1016","volume":"41","author":[{"given":"Simon","family":"Bowman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Barone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2012.05.024_bib0005","series-title":"Arthritis and allied conditions. Ch.\u00a078","first-page":"1681","article-title":"Sj\u00f6gren's syndrome","author":"Jonsson","year":"2005"},{"key":"10.1016\/j.lpm.2012.05.024_bib0010","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/art.1780390219","article-title":"Long-term follow-up of patients with Sj\u00f6gren's syndrome","volume":"39","author":"Kruize","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2012.05.024_bib0015","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1002\/1529-0131(199908)42:8<1765::AID-ANR28>3.0.CO;2-V","article-title":"Malignant lymphoma in primary Sj\u00f6gren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sj\u00f6gren's Syndrome","volume":"42","author":"Voulgarelis","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2012.05.024_bib0020","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/ard.2005.041186","article-title":"Lymphoma and other malignancies in primary Sj\u00f6gren's syndrome: a cohort study on cancer incidence and lymphoma predictors","volume":"65","author":"Theander","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2012.05.024_bib0025","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/03009740310004676","article-title":"Estimating the prevalence among Caucasian women of primary Sj\u00f6gren's syndrome in two general practices in Birmingham, UK","volume":"33","author":"Bowman","year":"2004","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0030","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1477-7525-7-46","article-title":"Primary Sj\u00f6gren's Syndrome: health experiences and predictors of health quality among patients in the United States","volume":"7","author":"Segal","year":"2009","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.lpm.2012.05.024_bib0035","series-title":"Sj\u00f6gren's Syndrome \u2013 practical guidelines to diagnosis and therapy. Ch.\u00a021","first-page":"357","article-title":"Fatigue, dryness and quality of life as clinical trial outcomes in primary Sj\u00f6gren's syndrome","author":"Bowman","year":"2011"},{"key":"10.1016\/j.lpm.2012.05.024_bib0040","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/rheumatology\/kel155","article-title":"Direct healthcare costs and predictors of costs in patients with primary Sj\u00f6gren's syndrome","volume":"46","author":"Callaghan","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.lpm.2012.05.024_bib0045","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.3899\/jrheum.090734","article-title":"Estimating indirect costs in primary Sj\u00f6gren's syndrome","volume":"37","author":"Bowman","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0050","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":"Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group","volume":"107","author":"Sall","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.lpm.2012.05.024_bib0055","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/archinte.159.2.174","article-title":"Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sj\u00f6gren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group","volume":"159","author":"Vivino","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.lpm.2012.05.024_bib0060","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1001\/archinte.162.11.1293","article-title":"Cevimeline for the treatment of xerostomia in patients with Sj\u00f6gren syndrome: a randomized trial","volume":"162","author":"Fife","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.lpm.2012.05.024_bib0065","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/ard.52.5.360","article-title":"Hydroxychloroquine treatment for primary Sj\u00f6gren's syndrome: a two-year double blind crossover trial","volume":"52","author":"Kruize","year":"1993","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2012.05.024_bib0070","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/ard.58.4.253","article-title":"Hydroxychloroquine treatment for primary Sj\u00f6gren's syndrome: its effect on salivary and serum inflammatory markers","volume":"58","author":"Tishler","year":"1999","journal-title":"Ann Rheum Dis"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.lpm.2012.05.024_bib0075","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1177\/096120339600500108","article-title":"Treatment of primary Sj\u00f6gren's syndrome with hydroxychloroquine: a retrospective, open-label study","volume":"5","author":"Fox","year":"1996","journal-title":"Lupus"},{"key":"10.1016\/j.lpm.2012.05.024_bib0080","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/rheumatology\/kep104","article-title":"Treatment of sicca symptoms with hydroxychloroquine in patients with Sj\u00f6gren's syndrome","volume":"48","author":"Rihl","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.lpm.2012.05.024_bib0085","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s00296-010-1415-4","article-title":"Hydroxychloroquine improves dry eye symptoms of patients with primary Sj\u00f6gren's syndrome","volume":"31","author":"Yavuz","year":"2001","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.lpm.2012.05.024_bib0090","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/rheumatology\/keh506","article-title":"Hydroxychloroquine therapy in patients with primary Sj\u00f6gren's syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase","volume":"44","author":"Dawson","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.lpm.2012.05.024_bib0095","first-page":"149","article-title":"Prednisone and piroxicam for treatment of primary Sj\u00f6gren's syndrome","volume":"11","author":"Fox","year":"1993","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0100","first-page":"896","article-title":"A double blind placebo controlled trial of azathioprine in the treatment of primary Sj\u00f6gren's syndrome","volume":"25","author":"Price","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0105","first-page":"555","article-title":"Methotrexate in primary Sj\u00f6gren's syndrome","volume":"14","author":"Skopouli","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0110","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/15027732.1986.12461421","article-title":"Cyclosporin a therapy in patients with primary Sj\u00f6gren's syndrome: results at one year","volume":"61","author":"Drosos","year":"1986","journal-title":"Scand J Rheumatol Suppl"},{"key":"10.1016\/j.lpm.2012.05.024_bib0115","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1136\/ard.2006.060905","article-title":"Safety and efficacy of leflunomide in primary Sj\u00f6gren's syndrome: a phase II pilot study","volume":"66","author":"van Woerkom","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2012.05.024_bib0120","doi-asserted-by":"crossref","first-page":"R115","DOI":"10.1186\/ar2322","article-title":"Mycophenolate sodium treatment in patients with primary Sj\u00f6gren syndrome: a pilot trial","volume":"9","author":"Willeke","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.lpm.2012.05.024_bib0125","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/01.md.0000141099.53742.16","article-title":"Neurologic manifestations in primary Sj\u00f6gren syndrome: a study of 82 patients","volume":"83","author":"Delalande","year":"2004","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.lpm.2012.05.024_bib0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0b013e31824125e4","article-title":"Prognosis and outcome of non-Hodgkin lymphoma in primary Sj\u00f6gren syndrome","volume":"91","author":"Voulgarelis","year":"2012","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.lpm.2012.05.024_bib0135","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.3899\/jrheum.110077","article-title":"Treatment of mucosa-associated lymphoid tissue lymphoma in Sj\u00f6gren's syndrome: a retrospective clinical study","volume":"38","author":"Pollard","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0140","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2012.05.024_bib0145","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1182\/blood-2002-11-3442","article-title":"Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)","volume":"101","author":"Mounier","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2012.05.024_bib0150","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.21260","article-title":"Rituximab treatment in patients with primary Sj\u00f6gren's syndrome: an open-label phase II study","volume":"52","author":"Pijpe","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2012.05.024_bib0155","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/ard.2008.092601","article-title":"Treatment of primary Sj\u00f6gren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment","volume":"68","author":"Meijer","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2012.05.024_bib0160","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard.2006.057919","article-title":"Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sj\u00f6gren's syndrome","volume":"66","author":"Seror","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.lpm.2012.05.024_bib0165","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00063030-200923020-00004","article-title":"Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response","volume":"23","author":"Gibbons","year":"2009","journal-title":"BioDrugs"},{"key":"10.1016\/j.lpm.2012.05.024_bib0170","doi-asserted-by":"crossref","DOI":"10.1002\/art.34400","article-title":"Belimumab reduces autoantibodies, normalizes low complement and reduces select B-cell populations in patients with systemic lupus erythematosus","author":"Stohl","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2012.05.024_bib0175","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/rheumatology\/keh170","article-title":"Measurement of fatigue and discomfort in primary Sj\u00f6gren's syndrome using a new questionnaire tool","volume":"43","author":"Bowman","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.lpm.2012.05.024_bib0180","first-page":"1259","article-title":"Validation of the Sicca Symptoms Inventory for clinical studies of Sj\u00f6gren's syndrome","volume":"30","author":"Bowman","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0185","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/rheumatology\/ken426","article-title":"Patient-reported outcomes in primary Sj\u00f6gren's syndrome: comparison of the long and short versions of the Profile of Fatigue and Discomfort\u2013Sicca Symptoms Inventory","volume":"48","author":"Bowman","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.lpm.2012.05.024_bib0190","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/ard.2010.143743","article-title":"EULAR Sj\u00f6gren's syndrome patients reported index (ESSPRI): development of a consensus index for primary Sj\u00f6gren's syndrome","volume":"70","author":"Seror","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2012.05.024_bib0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2012.01.013","article-title":"Outcome measures for primary Sj\u00f6gren's syndrome","author":"Seror","year":"2012","journal-title":"J Autoimmun"},{"key":"10.1016\/j.lpm.2012.05.024_bib0200","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/ard.2009.110619","article-title":"EULAR Sj\u00f6gren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sj\u00f6gren's syndrome","volume":"69","author":"Seror","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2012.05.024_bib0205","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/acr.20173","article-title":"Accurate detection of changes in disease activity in primary Sj\u00f6gren's syndrome by the European League against Rheumatism Sj\u00f6gren's syndrome disease activity index","volume":"62","author":"Seror","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.lpm.2012.05.024_bib0210","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1002\/art.22658","article-title":"Sj\u00f6gren's Syndrome Disease Damage Index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sj\u00f6gren's syndrome, derived from an analysis of a cohort of Italian patients","volume":"56","author":"Vitali","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2012.05.024_bib0215","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/rheumatology\/kem280","article-title":"Sj\u00f6gren's Systemic Clinical Activity Index (SCAI): a systemic disease activity measure for use in clinical trials in primary Sj\u00f6gren's syndrome","volume":"46","author":"Bowman","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.lpm.2012.05.024_bib0220","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/rheumatology\/ken164","article-title":"The Sj\u00f6gren's Syndrome Damage Index--a damage index for use in clinical trials and observational studies in primary Sj\u00f6gren's syndrome","volume":"47","author":"Barry","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.lpm.2012.05.024_bib0225","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1136\/ard.2011.152769","article-title":"BSR Biologics Register. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register","volume":"70","author":"Galloway","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2012.05.024_bib0230","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"BSR Biologics Register. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2012.05.024_bib0235","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","article-title":"Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2012.05.024_bib0240","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.semarthrit.2008.10.002","article-title":"The risk of infections with biologic therapies for rheumatoid arthritis","volume":"39","author":"Furst","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.lpm.2012.05.024_bib0245","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/art.33353","article-title":"Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight\u2013week randomized, double-blind, placebo-controlled, parallel-group phase III trial","volume":"64","author":"Tak","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2012.05.024_bib0250","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1002\/art.24966","article-title":"Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases","volume":"60","author":"Molloy","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2012.05.024_bib0255","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project","volume":"113","author":"Carson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2012.05.024_bib0260","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/acr.21564","article-title":"Incidence and risk factors for Progressive Multifocal Leukoencephalopathy among patients with selected rheumatic diseases","volume":"64","author":"Bharat","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.lpm.2012.05.024_bib0265","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/art.22604","article-title":"Will targeting B cells be the answer for Sj\u00f6gren's syndrome?","volume":"56","author":"Looney","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2012.05.024_bib0270","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1002\/art.11311","article-title":"Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sj\u00f6gren's syndrome","volume":"48","author":"Salomonsson","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2012.05.024_bib0275","first-page":"311","article-title":"Ultrasound assessment of salivary glands in patients with primary Sj\u00f6gren's syndrome treated with rituximab: quantitative and Doppler waveform analysis","volume":"1","author":"Jousse-Joulin","year":"2007","journal-title":"Biologics"},{"key":"10.1016\/j.lpm.2012.05.024_bib0280","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/CND.0b013e3181c50513","article-title":"Prolonged remission of a demyelinating neuropathy in a patient with lymphoma and Sj\u00f6gren's syndrome after rituximab therapy","volume":"11","author":"Botez","year":"2010","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1016\/j.lpm.2012.05.024_bib0285","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/rheumatology\/keh248","article-title":"Combined therapy with rituximab plus cyclophosphamide\/doxorubicin\/vincristine\/prednisone (CHOP) for Sj\u00f6gren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas","volume":"43","author":"Voulgarelis","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.lpm.2012.05.024_bib0290","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sj\u00f6gren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2012.05.024_bib0295","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/art.22603","article-title":"BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sj\u00f6gren's syndrome","volume":"56","author":"Pers","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2012.05.024_bib0300","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1002\/art.24903","article-title":"Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sj\u00f6gren's syndrome","volume":"60","author":"Pijpe","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2012.05.024_bib0305","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1002\/art.30236","article-title":"B cell reconstitution and T helper cell balance after rituximab treatment of active primary Sj\u00f6gren's syndrome: a double-blind, placebo-controlled study","volume":"63","author":"Abdulahad","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2012.05.024_bib0310","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/ard.2004.029694","article-title":"Club Rheumatismes et Inflammation (CRI). Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases","volume":"64","author":"Gottenberg","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2012.05.024_bib0315","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/art.22536","article-title":"Improvement of Sj\u00f6gren's syndrome after two infusions of rituximab (anti-CD20)","volume":"57","author":"Devauchelle-Pensec","year":"2007","journal-title":"Arthritis Care Res"},{"issue":"Supplement","key":"10.1016\/j.lpm.2012.05.024_bib0320","first-page":"S445","article-title":"Longitudinal analysis of lymphocyte subsets in patients with primary Sj\u00f6gren's syndrome (pSS) treated with rituximab: results from an open-label clinical trial","volume":"56","author":"Levesque","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2012.05.024_bib0325","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard.2007.083865","article-title":"Reduction of fatigue in Sj\u00f6gren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study","volume":"67","author":"Dass","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2012.05.024_bib0330","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sj\u00f6gren's syndrome: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2012.05.024_bib0335","doi-asserted-by":"crossref","first-page":"R129","DOI":"10.1186\/ar2018","article-title":"Epratuzumab (humanised anti-CD22 antibody) in primary Sj\u00f6gren's syndrome: an open-label phase I\/II study","volume":"8","author":"Steinfeld","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.lpm.2012.05.024_bib0340","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1126\/science.285.5425.260","article-title":"BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator","volume":"285","author":"Moore","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.lpm.2012.05.024_bib0345","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1084\/jem.189.11.1747","article-title":"BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth","volume":"189","author":"Schneider","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.lpm.2012.05.024_bib0350","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1084\/jem.190.11.1697","article-title":"Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations","volume":"190","author":"Mackay","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.lpm.2012.05.024_bib0355","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/ard.62.2.168","article-title":"The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sj\u00f6gren's syndrome","volume":"62","author":"Mariette","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2012.05.024_bib0360","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1196\/annals.1313.004","article-title":"BAFF overexpression is associated with autoantibody production in autoimmune diseases","volume":"1050","author":"Pers","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.lpm.2012.05.024_bib0365","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10875-005-4091-5","article-title":"Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sj\u00f6gren's syndrome","volume":"25","author":"Jonsson","year":"2005","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0370","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/rheumatology\/ken246","article-title":"Polymorphism in the 5\u2019 regulatory region of the B-lymphocyte activating factor gene is associated with the Ro\/La autoantibody response and serum BAFF levels in primary Sj\u00f6gren's syndrome","volume":"47","author":"Nossent","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.lpm.2012.05.024_bib0375","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-3083.2007.02049.x","article-title":"B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sj\u00f6gren's syndrome","volume":"67","author":"Lavie","year":"2008","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0380","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.clim.2005.06.016","article-title":"Distinct profiles of Sj\u00f6gren's syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF","volume":"117","author":"Szodoray","year":"2005","journal-title":"Clin Immunol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0385","doi-asserted-by":"crossref","first-page":"R51","DOI":"10.1186\/ar1912","article-title":"B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sj\u00f6gren's syndrome","volume":"8","author":"Ittah","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.lpm.2012.05.024_bib0390","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/art.22458","article-title":"Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sj\u00f6gren's syndrome","volume":"56","author":"Daridon","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2012.05.024_bib0395","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1002\/eji.200738113","article-title":"Deficiency of Act1, a critical modulator of B cell function, leads to development of Sj\u00f6gren's syndrome","volume":"38","author":"Qian","year":"2008","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0400","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/ard.2006.060772","article-title":"Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production","volume":"66","author":"Lavie","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2012.05.024_bib0405","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2174\/1874312900802010038","article-title":"Resistance to rituximab therapy and local BAFF overexpression in Sj\u00f6gren's syndrome-related myoepithelial sialadenitis and low-grade parotid b-cell lymphoma","volume":"2","author":"Quartuccio","year":"2008","journal-title":"Open Rheumatol J"},{"issue":"2","key":"10.1016\/j.lpm.2012.05.024_bib0410","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/ar2976","article-title":"Systemic lupus erythematosus and its ABCs (APRIL\/BLyS complexes","volume":"12","author":"Stohl","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.lpm.2012.05.024_bib0415","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2011-200937","article-title":"Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response","author":"van Vollenhoven","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.lpm.2012.05.024_bib0420","doi-asserted-by":"crossref","first-page":"R33","DOI":"10.1186\/ar3738","article-title":"Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial","volume":"14","author":"Ginzler","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.lpm.2012.05.024_bib0425","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/eji.200738013","article-title":"Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR- and type-I IFN-dependent and -independent pathways","volume":"38","author":"Ittah","year":"2008","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0430","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","article-title":"Inefficacy of infliximab in primary Sj\u00f6gren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sj\u00f6gren's Syndrome (TRIPSS)","volume":"50","author":"Mariette","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2012.05.024_bib0435","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.20299","article-title":"Etanercept in Sj\u00f6gren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial","volume":"50","author":"Sankar","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2012.05.024_bib0440","first-page":"96","article-title":"Etanercept in the treatment of patients with primary Sj\u00f6gren's syndrome: a pilot study","volume":"31","author":"Zandbelt","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0445","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1002\/art.23062","article-title":"Augmented interferon-alpha pathway activation in patients with Sj\u00f6gren's syndrome treated with etanercept","volume":"56","author":"Mavragani","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2012.05.024_bib0450","doi-asserted-by":"crossref","first-page":"e30123","DOI":"10.1371\/journal.pone.0030123","article-title":"Interleukin-1 inhibition and fatigue in primary Sj\u00f6gren's syndrome \u2013 a double blind randomized clinical trial","volume":"7","author":"Norheim","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.lpm.2012.05.024_bib0455","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jaut.2009.02.013","article-title":"The weight of interleukin-6 in B cell-related autoimmune disorders","volume":"32","author":"Youinou","year":"2009","journal-title":"J Autoimmun"},{"key":"10.1016\/j.lpm.2012.05.024_bib0460","first-page":"189","article-title":"Increased production of interleukin-6 and autoantibodies in patients with Sj\u00f6gren's syndrome","volume":"25","author":"Wen","year":"1992","journal-title":"Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi"},{"key":"10.1016\/j.lpm.2012.05.024_bib0465","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.4049\/jimmunol.152.11.5532","article-title":"Cytokine mRNA expression in salivary gland biopsies of Sj\u00f6gren's syndrome","volume":"152","author":"Fox","year":"1994","journal-title":"J Immunol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0470","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/rheumatology\/34.4.326","article-title":"Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sj\u00f6gren's syndrome","volume":"34","author":"Boumba","year":"1995","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0475","first-page":"1674","article-title":"Local cytokine expression in the progression toward B cell malignancy in Sj\u00f6gren's syndrome","volume":"22","author":"De Vita","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0480","first-page":"1089","article-title":"Salivary and serum interleukin 6 in primary Sj\u00f6gren's syndrome","volume":"24","author":"Grisius","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0485","first-page":"411","article-title":"Circulating levels of Th1\/Th2 cytokines in patients with primary Sj\u00f6gren's syndrome: correlation with clinical and immunological features","volume":"19","author":"Garc\u00edc-Carrasco","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0490","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.0300-9475.2004.01432.x","article-title":"Circulating cytokines in primary Sj\u00f6gren's syndrome determined by a multiplex cytokine array system","volume":"59","author":"Szodoray","year":"2004","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0495","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cellimm.2009.05.013","article-title":"Implications of immunomodulatory interleukins for the hyperimmunoglobulinemia of Sj\u00f6gren's syndrome","volume":"259","author":"Gir\u00f3n-Gonz\u00e1lez","year":"2009","journal-title":"Cell Immunol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0500","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2353\/ajpath.2009.090319","article-title":"Systemic and local interleukin-17 and linked cytokines associated with Sj\u00f6gren's syndrome immunopathogenesis","volume":"175","author":"Katsifis","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0505","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1046\/j.1365-3083.1999.00533.x","article-title":"Increased frequency of cells secreting interleukin-6 and interleukin-10 in peripheral blood of patients with primary Sj\u00f6gren's syndrome","volume":"49","author":"Halse","year":"1999","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0510","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1136\/ard.2003.011825","article-title":"Serum cytokine levels related to multiple dimensions of fatigue in patients with primary Sj\u00f6gren's syndrome","volume":"63","author":"Hartkamp","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2012.05.024_bib0515","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1080\/03009740902973821","article-title":"Health-related quality of life in patients with primary Sj\u00f6gren's syndrome: relationship with serum levels of proinflammatory cytokines","volume":"38","author":"Baturone","year":"2009","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0520","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/ard.2008.091256","article-title":"Interleukin 6 and its soluble receptor in a central role at the neuroimmunoendocrine interface in Sj\u00f6gren syndrome: an explanatory interventional study","volume":"68","author":"d\u2019Elia","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2012.05.024_bib0525","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2008.092866","article-title":"Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study","volume":"68","author":"Nishimoto","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2012.05.024_bib0530","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3899\/jrheum.080813","article-title":"Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study","volume":"36","author":"Westhovens","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0535","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.4049\/jimmunol.182.3.1421","article-title":"B7RP-1 blockade ameliorates autoimmunity through regulation of follicular helper T cells","volume":"182","author":"Hu","year":"2009","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.lpm.2012.05.024_bib0540","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1517\/17425251003641967","article-title":"Alefacept: where it stands today","volume":"6","author":"Chaarani","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0545","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archderm.139.6.719","article-title":"An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis","volume":"139","author":"Lebwohl","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0550","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jaut.2006.02.002","article-title":"Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases","volume":"26","author":"Goules","year":"2006","journal-title":"J Autoimmun"},{"key":"10.1016\/j.lpm.2012.05.024_bib0555","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1046\/j.1365-2249.2002.01752.x","article-title":"CD40 on salivary gland epithelial cells: high constitutive expression by cultured cells from Sj\u00f6gren's syndrome patients indicating their intrinsic activation","volume":"127","author":"Dimitriou","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0560","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/art.10856","article-title":"BG9588 Lupus Nephritis Trial Group. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis","volume":"48","author":"Boumpas","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2012.05.024_bib0565","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1002\/art.10681","article-title":"Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Kalunian","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2012.05.024_bib0570","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/rheumatology\/kep149","article-title":"Cytokine and autoantibody profiling related to histopathological features in primary Sj\u00f6gren's syndrome","volume":"48","author":"Reksten","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.lpm.2012.05.024_bib0575","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/art.20998","article-title":"Activation of the type I interferon system in primary Sj\u00f6gren's syndrome: a possible etiopathogenic mechanism","volume":"52","author":"Bave","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2012.05.024_bib0580","doi-asserted-by":"crossref","first-page":"R447","DOI":"10.1186\/ar1209","article-title":"Increased circulating levels and salivary gland expression of interleukin-18 in patients with Sj\u00f6gren's syndrome: relationship with autoantibody production and lymphoid organization of the periductal inflammatory infiltrate","volume":"6","author":"Bombardieri","year":"2004","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.lpm.2012.05.024_bib0585","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.4049\/jimmunol.181.4.2898","article-title":"Identification of IL-18 and Th17 cells in salivary glands of patients with Sj\u00f6gren's syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18","volume":"181","author":"Sakai","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0590","doi-asserted-by":"crossref","first-page":"R179","DOI":"10.1186\/ar3504","article-title":"Impact of interleukin-21 in the pathogenesis of primary Sj\u00f6gren's syndrome: increased serum levels of interleukin-21 and its expression in the labial salivary glands","volume":"13","author":"Kang","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.lpm.2012.05.024_bib0595","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1136\/ard.2011.154013","article-title":"Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sj\u00f6gren's syndrome","volume":"71","author":"Ciccia","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2012.05.024_bib0600","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1002\/art.24980","article-title":"Interleukin-12 induces salivary gland dysfunction in transgenic mice, providing a new model of Sj\u00f6gren's syndrome","volume":"60","author":"Vosters","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2012.05.024_bib0605","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1089\/02724570050198875","article-title":"Characterization of the in vitro and in vivo activity of monoclonal antibodies to human IL-18","volume":"19","author":"Holmes","year":"2000","journal-title":"Hybridoma"},{"issue":"5","key":"10.1016\/j.lpm.2012.05.024_bib0610","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.lpm.2012.05.024_bib0615","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/gene.2010.29","article-title":"STAT4 is a confirmed genetic risk factor for Sj\u00f6gren's syndrome and could be involved in type 1 interferon pathway signalling","volume":"11","author":"Gestermann","year":"2010","journal-title":"Genes Immun"},{"key":"10.1016\/j.lpm.2012.05.024_bib0620","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1002\/art.23142","article-title":"Association of an IRF5 gene functional polymorphism with Sj\u00f6gren's syndrome","volume":"56","author":"Miceli-Richard","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2012.05.024_bib0625","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1136\/ard.2010.144485","article-title":"Safety profile and clinical activity of sifalimumab, a fully human anti-interferon \u03b1 monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study","volume":"70","author":"Merrill","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2012.05.024_bib0630","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1600-0714.2008.00700.x","article-title":"Activation of innate immune responses through Toll-like receptor 3 causes a rapid loss of salivary gland function","volume":"38","author":"Deshmukh","year":"2009","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.lpm.2012.05.024_bib0635","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1073\/pnas.0510837103","article-title":"Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sj\u00f6gren's syndrome","volume":"103","author":"Gottenberg","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.lpm.2012.05.024_bib0640","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1365-2249.2006.03311.x","article-title":"Expression of functional Toll-like receptors by salivary gland epithelial cells: increased mRNA expression in cells derived from patients with primary Sj\u00f6gren's syndrome","volume":"147","author":"Spachidou","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0645","first-page":"1019","article-title":"Toll-like receptor in salivary glands from patients with Sj\u00f6gren's syndrome: functional analysis by human salivary gland cell line","volume":"34","author":"Kawakami","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0650","doi-asserted-by":"crossref","first-page":"R64","DOI":"10.1186\/ar3780","article-title":"TLR2 ligation induces the production of IL-23\/IL-17 via IL-6, STAT3 and NF-kB pathway in patients with primary Sj\u00f6gren's syndrome","volume":"14","author":"Kwok","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.lpm.2012.05.024_bib0655","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1600-065X.2008.00630.x","article-title":"Development of TLR inhibitors for the treatment of autoimmune diseases","volume":"223","author":"Barrat","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.lpm.2012.05.024_bib0660","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1089\/107999099313497","article-title":"Treatment of primary Sj\u00f6gren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. IFN Protocol Study Group","volume":"19","author":"Ship","year":"1999","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.lpm.2012.05.024_bib0665","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1002\/art.21062","article-title":"Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sj\u00f6gren's syndrome","volume":"52","author":"Barone","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2012.05.024_bib0670","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/1529-0131(200102)44:2<408::AID-ANR60>3.0.CO;2-0","article-title":"\u201cLymphoid\u201d chemokine messenger RNA expression by epithelial cells in the chronic inflammatory lesion of the salivary glands of Sj\u00f6gren's syndrome patients: possible participation in lymphoid structure formation","volume":"44","author":"Xanthou","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2012.05.024_bib0675","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1002\/1529-0131(200111)44:11<2633::AID-ART443>3.0.CO;2-9","article-title":"Ectopic expression of the B cell-attracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center-like structures in Sj\u00f6gren's syndrome","volume":"44","author":"Amft","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2012.05.024_bib0680","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1517\/13543780903535867","article-title":"Anti-chemokine small molecule drugs: a promising future?","volume":"19","author":"Proudfoot","year":"2010","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.lpm.2012.05.024_bib0685","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1006\/clin.1996.0094","article-title":"Expression of selectins (CD62 E,L,P) and cellular adhesion molecules in primary Sj\u00f6gren's syndrome: questions to immunoregulation","volume":"80","author":"Aziz","year":"1996","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0690","first-page":"1063","article-title":"Vasculitis and expression of vascular cell adhesion molecule-1, intercellular adhesion molecule-1, and E-selectin in salivary glands of patients with Sj\u00f6gren's syndrome","volume":"32","author":"Turkcapar","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0695","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0002-9440(10)61738-5","article-title":"Lymphocyte migration to inflamed lacrimal glands is mediated by vascular cell adhesion molecule-1\/alpha(4)beta(1) integrin, peripheral node addressin\/l-selectin, and lymphocyte function-associated antigen-1 adhesion pathways","volume":"159","author":"Mikulowska-Mennis","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0700","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/ard.54.3.209","article-title":"Cytokine and adhesion molecule expression in the minor salivary glands of patients with Sj\u00f6gren's syndrome and chronic sialoadenitis","volume":"54","author":"Cauli","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2012.05.024_bib0705","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1365-2249.2007.03448.x","article-title":"Amelioration of lacrimal gland inflammation by oral administration of K-13182 in Sj\u00f6gren's syndrome model mice","volume":"149","author":"Nishiyama","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0710","first-page":"1295","article-title":"Vedolizumab, a humanized mAb against the \u03b14\u03b27 integrin for the potential treatment of ulcerative colitis and Crohn's disease","volume":"11","author":"Tilg","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.lpm.2012.05.024_bib0715","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1046\/j.1365-3083.1999.00490.x","article-title":"An alternative perspective to the immune response in autoimmune exocrinopathy: induction of functional quiescence rather than destructive autoaggression","volume":"49","author":"Humphreys-Beher","year":"1999","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0720","first-page":"925","article-title":"Impaired neurotransmitter release from lacrimal and salivary gland nerves of a murine model of Sj\u00f6gren's syndrome","volume":"42","author":"Zoukhri","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.lpm.2012.05.024_bib0725","doi-asserted-by":"crossref","first-page":"C1191","DOI":"10.1152\/ajpcell.00144.2008","article-title":"Proinflammatory cytokines tumor necrosis factor-alpha and interferon-gamma alter tight junction structure and function in the rat parotid gland Par-C10 cell line","volume":"295","author":"Baker","year":"2008","journal-title":"Am J Physiol Cell Physiol"},{"issue":"6","key":"10.1016\/j.lpm.2012.05.024_bib0730","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1167\/iovs.09-4212","article-title":"Pharmacological cholinergic blockade stimulates inflammatory cytokine production and lymphocytic infiltration in the mouse lacrimal gland","volume":"52","author":"Pitcher","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.lpm.2012.05.024_bib0735","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev.physiol.67.041703.084745","article-title":"Regulation of fluid and electrolyte secretion in salivary gland acinar cells","volume":"67","author":"Melvin","year":"2005","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.lpm.2012.05.024_bib0740","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1601-0825.2011.01819.x","article-title":"Loss of PKC\u03b4 results in characteristics of Sj\u00f6gren's syndrome including salivary gland dysfunction","volume":"17","author":"Banninger","year":"2011","journal-title":"Oral Dis"},{"key":"10.1016\/j.lpm.2012.05.024_bib0745","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1177\/0022034511422817","article-title":"Role of calcium and PKC in salivary mucous cell exocrine secretion","volume":"90","author":"Culp","year":"2011","journal-title":"J Dent Res"},{"key":"10.1016\/j.lpm.2012.05.024_bib0750","article-title":"Biologic therapies in Primary Sj\u00f6gren's syndrome","author":"Bowman","year":"2012","journal-title":"Curr Pharm Biotechnol"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498212003855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498212003855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T09:55:53Z","timestamp":1743846953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498212003855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":150,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0755498212003855"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2012.05.024","relation":{},"ISSN":["0755-4982"],"issn-type":[{"type":"print","value":"0755-4982"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}